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and Darren M. Ashcroft 1,4Abstract
Background: Monitoring for potentially hazardous prescribing is increasingly important to improve medication
safety. Healthcare information technology can be used to achieve this aim, for example by providing access to
prescribing data through surveillance of patients’ electronic health records. The aim of our study was to examine
the implementation and adoption of an electronic medicines optimisation system that was intended to facilitate
clinical audit in primary care by identifying patients at risk of an adverse drug event. We adopted a sociotechnical
approach that focuses on how complex social, organisational and institutional factors may impact upon the use of
technology within work settings.
Methods: We undertook a qualitative realist evaluation of the use of an electronic medicines optimisation system in
one Clinical Commissioning Group in England. Five semi-structured interviews, four focus groups and one observation
were conducted with a range of stakeholders. Consistent with a realist evaluation methodology, the analysis focused
on exploring the links between context, mechanism and outcome to explain the ways the intervention might work, for
whom and in what circumstances.
Results: Using the electronic medicines optimisation system could lead to a number of improved patient safety
outcomes including pre-emptively reviewing patients at risk of adverse drug events. The effective use of the system
depended upon engagement with the system, the flow of information between different health professionals centrally
placed at the Clinical Commissioning Group and those locally placed at individual general practices, and upon variably
adapting work practices to facilitate the use of the system. The use of the system was undermined by perceptions of
ownership, lack of access, and lack of knowledge and awareness.
Conclusions: The use of an electronic medicines optimisation system may improve medication safety in primary care
settings by identifying those patients at risk of an adverse drug event. To fully realise the potential benefits for medication
safety there needs to be better utilisation across primary care and with a wider range of stakeholders. Engaging with all
potential stakeholders and users prior to implementation of such systems might allay perceptions that the system is
owned centrally and increase knowledge of the potential benefits.
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Recent studies examining prescribing of medicines in pri-
mary care have highlighted the risks associated with this
activity [1]. For example, one study estimated that approxi-
mately 13% of patients have experienced an adverse drug
event (ADE) after receiving prescription medication in pri-
mary care and that many are serious enough to require
hospital attention [2]. In addition, an estimated 8–12% of
all hospital admissions are caused by ADEs, of which
around 50% are preventable [2, 3]. Not only is there an in-
creasing volume of prescribing in primary care (currently
over 1 billion prescription items per year in England alone)
[4], but increasing numbers of patients with multi-
morbidities have led to a greater prevalence of polyphar-
macy [5], increasing the likelihood of an ADE [6, 7]. This
makes the monitoring of medication use increasingly im-
portant for primary care patient safety.
Healthcare information technology (IT) can offer poten-
tial benefits for medication safety [8] for instance by pro-
viding easier access to prescribing data, facilitating
clinicians’ assessments of the quality and safety of prescrib-
ing [1, 9, 10]. Lainer and colleagues [11] systematically
reviewed randomized controlled trials of IT interventions
including computerized physician order entry, clinical deci-
sion support systems and pharmacy information manage-
ment systems. They concluded that these interventions
successfully reduced medication errors but only for a lim-
ited number of clearly defined errors. Clearly, IT needs
careful implementation to avoid its effectiveness being im-
paired by human factors such as alert fatigue and user in-
experience [12]. Within primary care, the implementation
of clinical decision support systems has been reported to
lack compatibility with the general practitioner’s (GP) pre-
existing work practices because these systems were found
to correct decisions retrospectively, rather than provide
guidance beforehand [13]. Meanwhile, the PINCER trial
[14] found that an IT-based intervention to identify and
correct medication errors in general practice was more ef-
fective when combined with dedicated support from a clin-
ical pharmacist; the latter acting as a “change agent” who
built working relationships with the practice staff [15].
From a sociotechnical perspective healthcare interven-
tions involving the implementation of IT may be under-
stood as complex interactions and interdependencies
between the working practices of people using the technol-
ogy, the organisational and social context, and the technol-
ogy itself [16–20]. Such an approach takes into account the
complex nature of healthcare and the organisational aspects
of the workplaces in which interventions are implemented
[13]. The current study examines the implementation of an
electronic medicines optimisation system, (EMOS) that was
designed to support primary care medicines optimisation
[21]. Previous studies have not explored such a broad
EMOS and how its utilisation may depend on a range ofsocial and organisational factors. With that in mind, we
aimed to examine how an EMOS was used for medicines
safety activities in a primary care setting.
Methods
Study design and setting
Our research used a qualitative case study design, in-
formed by the realist evaluation methodology (explained
later). The study case was a clinical commissioning
group in the South of England. In the English National
Health Service (NHS), a Clinical Commissioning Group
(CCG) is a clinically-led statutory NHS body responsible
for the planning and commissioning of health care ser-
vices for their local area, and cover a group of general
practices within a local area. Whilst CCGs are made up
of member practices they operate centrally providing
support and governance to general practices that provide
primary medical care as independent contractors.
Within many CCGs a group of pharmacists, managers
and other healthcare professionals are centrally placed
and work as a medicines management team to optimise
the quality and safety of prescribed medicines.
The CCG that forms our study was chosen because it
was an early adopter of Eclipse Live, [21] the EMOS ex-
amined in this study, with all general practices signed up
to the system. All practices used the same GP clinical IT
system (In Practice Systems Vision). The sampling frame
for data collection was stakeholders within the CCG’s
geographical area who were using the system or poten-
tial users who were aware of it. This included doctors,
pharmacists, healthcare managers and patients.
The EMOS examined in this study comprises a web-
based user interface which securely extracts patient data
from general practice patient records. Accessed separately
from the general practitioners’ clinical systems, it allows
different stakeholders access to real time anonymized
patient data including medical histories of diagnoses, pre-
scribed medications and test results. The use of the EMOS
is intended to facilitate clinical audits of prescribing activ-
ity to identify patients at risk of ADEs, such as those re-
ceiving inappropriate combinations of drugs or not
appropriately monitored. Patients can access the system
through a “Patient Passport” that allows them to securely
log on, view their medications and view and upload test
results [21]. The EMOS allows clinicians to audit prescrib-
ing activity across a health care organisation and make
comparisons against national guidelines.
Recruitment and data collection
Individual participants were recruited on a purposive
basis via the CCG or through community pharmacy net-
works, to represent the different stakeholder groups (see
Table 1). Potential participants were contacted by tele-
phone or email. To assist with recruitment and to allow
Table 1 Participants and recruitment
Participants Role Use of EMOS
Interviews
GP1-INT General
Practitioner
In general practice and as prescribing
lead of Clinical Commissioning Group
(CCG) medicines management team
GP2 General
Practitioner
In general practice and as respiratory
lead at CCG
GP3 General
Practitioner
In general practice
CCGP1 CCG Pharmacist Medication reviews in care homes
CCGP2 CCG Pharmacist CCG medicines management team
Focus group A - General Practitioners
GP4 General
Practitioner
In general practice
GP1-FG General
Practitioner
In practice and as prescribing lead of
CCG medicines management team
Focus group B – Community Pharmacists
CP1 Community
Pharmacist
Aware of, but no access
CP2 Community
Pharmacist
Aware of, but no access
CP3 Community
Pharmacist
Aware of, but no access
CP4 Community
Pharmacist
Aware of, but no access
Focus Group C – Patients
Pt1 Patient Access through patient passport
Pt2 Patient Access through patient passport
Pt3 Patient Access through patient passport
Pt4 Patient Access through patient passport
Focus Group D - General practice managers
GPM1 General
Practice
Manager
In general practice
GPM2 General
Practice
Manager
In general practice
GPM3 General
Practice
Manager
In general practice
GPM4 General
Practice
Manager
In general practice
Observation
CCGP1 CCG Pharmacist Medication reviews in care homes
A number of possible participants were approached but declined to
participate. Predominantly this was for reasons of time, workload or lack of
use of the system. These included 2 pharmacist technicians, 2 GPs, 2
community pharmacists and 8 general practice managers
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the use of the EMOS informal discussions took place
with users at two separate CCG sites; the study site and
a CCG in the North of England. Five semi-structuredinterviews (lasting between 20 and 50 min) were con-
ducted with three GPs and two CCG pharmacists, who
were known to be using the system, between August and
December 2014. Four homogeneous focus groups (last-
ing between 57 and 112 min) were conducted between
September and December 2014, each with a specific
group of stakeholders: GPs (2); community pharmacists
(4); patients (4); and general practice managers (4). In
the interviews and focus groups we explored experiences
of working with the EMOS, perceptions of the system,
benefits and drawbacks, the organisational structures
and roles required for its use and the circumstances
under which it was considered most effective. Data col-
lection continued until saturation was reached and no
new themes emerged from the interviews and focus
groups.
In addition, one observation was conducted of the sys-
tem being used in practice (December 2014). Researcher
MJ observed a CCG pharmacist at her usual workplace
for a two-hour period, during which the pharmacist used
the EMOS to conduct medication reviews of elderly care
home patients. Field notes from the observation were
added to the data set. The interviews, focus groups and
observation were carried out by a male researcher
trained and experienced in qualitative health research
(MJ). The focus groups were co-facilitated by a female
research pharmacist experienced in qualitative method-
ology (RLH). The researchers were not known to the
participants prior to the study. Four interviews were
conducted by telephone and one at the CCG offices, the
focus groups were conducted at the CCG offices or at a
local hotel. All participants gave written informed con-
sent to take part in the study, and for the interviews and
focus groups to be audio recorded and transcribed ver-
batim. Ethical approval for the study was granted by the
NHS National Research Ethics Service (reference 14/
NW/0113).
Methodological approach: realist evaluation
Complex interventions, such as those involving the imple-
mentation of healthcare IT, can be understood from a
“realist evaluation” perspective which seeks to explain the
ways the intervention might work, for whom and under
what circumstances [22, 23]. Realist evaluation draws from
realist philosophy in which human action is seen as occur-
ring within different layers of social reality. Actions only
make sense if they are considered as part of this social
reality with its associated rules, social norms and regula-
tions [23]. Realist evaluation asserts that a set of outcomes
is the product of particular responses from human and
technological actors within the system (“mechanisms”).
These mechanisms are activated in a given set of organisa-
tional or social circumstances (“context”) [23, 24]. A com-
bination of contexts and the associated mechanisms leads
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plexity of healthcare interventions, [25–27] realist evalu-
ation provides a detailed understanding of what makes an
intervention work, rather than a simple cause-and-effect re-
lationship between an intervention and its outcome(s). The
latter can indicate whether or not an intervention has
worked, but provides limited insights into how or why the
identified outcomes were obtained [23, 24]. Realist evalu-
ation presents these findings as a set of links between
contexts, mechanisms and outcomes (so-called “CMO con-
figurations”) (Fig. 1) [22–24, 28–30].
Analysis
Consistent with qualitative realist evaluation the analysis
was cumulative and iterative [22–24, 28–30]. The data
were analysed using a thematic approach, with each theme
representing a set of CMO configurations (CMOs). Similar
to previous realist evaluations [24, 31] an a priori set of
CMOs was developed deductively from available literature
[12–15, 19, 32] and informal discussions with users of the
EMOS. These included ways in which the intervention led
to changes in work practices [12], changes to the flow of
information [13, 32] and the goals of the system. These
provided the initial thematic framework for data analysis.
Early findings were discussed in subsequent focus groups
in an iterative approach consistent with realist evaluation
[23]. Transcripts of the interviews and focus groups were
read and discussed across the research team. A set of the-
matic codes, based on the initial framework, was applied to
the transcripts using the QSR Nvivo 10 application to or-
ganise the data. These codes identified potential outcomesFig. 1 Realist Evaluation: Context Mechanism Outcome Configurations.
Context: Pre-existing organisational, social or cultural circumstances.
Intervention: Implemented into specific context. Mechanism: Specific
and particular responses from human actors to the delivery of the
intervention. Outcomes: product of mechanisms activated within the
specific contextof the intervention. The outcomes were then grouped
under new themes that emerged from the data. Finally,
having determined what the outcomes were, we interro-
gated the data further for the mechanisms and contexts
that might have led to them. Hence, we generated CMO
configurations from the data which in turn were further
organised thematically into the three groups detailed in the
results below. The data coding and analysis were led by
MJ, with regular discussions about codes and emerging
themes and CMO configurations held with all co-authors,
including a patient representative.
Results
Consistent with a realist evaluation the findings were con-
ceptualised as CMO configurations; the circumstances and
ways in which the EMOS was used were perceived to lead
to a number of medication safety outcomes. These CMOs
were organised into three groups based upon the ways the
system was utilised: access; engagement or disengagement
with the system; the monitoring of prescribing; and work
practices. Within each group we identified mechanisms,
and contexts within which these mechanisms were acti-
vated, that led to given medication safety outcomes such
as patients’ electronic health records being screened to
identify potentially hazardous prescribing events.
Engagement and disengagement
The first group of CMOs concerned access, engagement
and disengagement (Tables 2 and 3). In the first of these
CMOs, the EMOS focused healthcare users’ attention on
medication rather than on disease.
“Say you are monitoring renal function and you look
and the eGFR [patient’s filtration rate] has gone down
to 29 and it was 31 the month before. You’re thinking,
well that’s okay, we’ll just monitor that, you fail
sometimes, […] one fails to think, ah, I need to review
the allopurinol, I need to renew the metformin,
because it is so, so, easy to focus on a disease and
that’s, I think, where Eclipse can come in. (GP1-INT)
Engagement with the system by GPs could therefore
lead to more focused patient reviews. The system could
be used for feedback, giving them “some idea as to who’s
perhaps even more engaged than others” (CCGP2). If ac-
tivated, this mechanism could “inform the CCG about
how well safety initiatives are happening” (CCGP2) and
lead to a speedier audit and feedback of safety initiatives
rolled out centrally.
Increased engagement with safer prescribing could be
sustained by voluntary engagement with the EMOS on
the part of the practices; this was said to reduce a “big-
brother” (GP1-INT) relationship with the CCG, chal-
lenge the belief that it was a tool primarily for the CCG
Table 2 Context-Mechanism-Outcome configurations concerning access and engagement
Context Mechanism Outcome
General Practitioner monitoring individual patients Focuses attention on
medications
Attention focused on patients most in need of review
General Practitioner prescribing audited and
monitored in practices
Proactively conducting
own audits
Practice prescribing patterns benchmarked against each
other across the Clinical Commissioning Group
Communication between Clinical Commissioning
Group and General Practitioner
Real time feedback Patients reviewed to ensure appropriate monitoring, to
optimise medications, or to avoid dangerous combinations
of drugs
Clinical Commissioning Group conducting searches
of prescribing based upon “projects” and “initiatives”
Prescribing patterns and trends benchmarked against
national targets and guidelines
Clinical Commissioning Group encouraging clinicians
to be engaged in more proactive safety management
Engagement of practices in
using the system for feedback
Voluntary engagement by
clinicians
Audits conducted as a means
of support to General
Practitioners
The effectiveness of safety initiatives audited more quickly
Improved engagement with safety monitoring of prescribing
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the system within general practice. However, GPs could
instead end up relying upon the medicines management
team to send out alerts, disengaging them from pro-
actively using the system and reinforcing CCG owner-
ship. Engagement was to be encouraged financially in
the future by building a requirement to use the EMOS
into the “prescribing incentive scheme” (CCGP2). In con-
trast, engagement was discouraged by blocking mecha-
nisms in the context of IT use in general practice. One
GP (GP2) stated that they and only one other colleague
used the EMOS. Such task allocation meant that within
their practice they operated as a prescribing lead where
they took responsibility for auditing and monitoring the
prescribing within their practice, and therefore were the
only ones expected to use the system. Another GP
remarked, in terms of seeing alerts in the system, “I don’t
commonly open the software full stop” (GP4) a barrier
that was related to time pressures:-Table 3 Context-Mechanism-Outcome configurations concerning d
Context Blocking Mech
Communication between Clinical Commissioning
Group and general practitioners
Feedback on a
logging in
Reliance on ale
out centrally
Information technology use in General Practice Lack of use/no
the system
Community pharmacists conducting medicine
use reviews with patients
No access to a
information
Community Pharmacy Perceived con
ownership
Patients using the electronic medicines
optimisation system
Facilitated use
professional
Difficulties obt
and logging o“a third of my time (is) seeing patients, two-thirds of
my time doing paperwork and an extra mystical 10 or
20% of time […] Eclipse fits into that last 10, 20% of
time that doesn’t really exist.” (GP4)
Other stakeholders were also disengaged from the sys-
tem. Community pharmacists were aware of it and per-
ceived potential benefits involving increased information
through access to care records that could inform medi-
cines use reviews, improve communication with GPs and
“influence a decision to sell a medicine or supply a medi-
cine.” (CP3). However, they had not been given access by
the CCG, nor had access through the “Patient Passport”,
though such access had been planned. This was attributed
to perceived difficulties with sharing information, issues of
confidentiality and a perception that “GPs often see them-
selves as the custodian of the patient record” (CP3) which
meant “historically a barrier to sharing that information”
(CP3). Community pharmacists had been involved inisengagement
anism Outcome not achieved
lerts requires Potential delays in patients being reviewed
rts being sent
t logging in to Potential delays in review of patients
dditional Opportunity for more appropriate and
directed medication review lost
flict and lack of Limits potential improvements in quality
of care for patients
by healthcare Lack of direct access to information to
benefit shared care and self-management
aining passwords
n
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cess to the EMOS but issues of confidentiality, delays and
poor communication with the CCG and general practices
had led to them being denied access.
A limited number of patients had access to the EMOS
through the patient passport. They saw this as poten-
tially valuable in giving access to information about
medications and their conditions, which would in turn
have a positive bearing on self-management and shared
care. However, this was prevented by a blocking mecha-
nisms concerning access, “The first problem I had was I
couldn’t log in at all” (P2). Patients also felt that they
would get best use out of the system if this was facili-
tated and interpreted by a health professional.
“I think that’s why it’s important to, it’s not just to be
used on its own, it’s to be used with, to be used with a
clinician of some kind to actually help you to interpret
some of that stuff, because some of it is, I mean when
you look at high haemoglobin levels or the glucose
levels, […] Which are the bad ones? Which is this?
What does this mean? “(P1)
The monitoring of prescribing
The monitoring of prescribing across general practices
(see Table 4) was undertaken by pharmacists and GPs
placed centrally at the CCG.
We identified two contexts within which mechanisms
were activated. The first of these concerned the engage-
ment with prescribing alerts issued by the CCG. Alerts that
related to the implementation of national guidance were
designed and disseminated to general practices. These
allowed for bespoke searches of prescribing data to be run
across all general practices within the CCG. This in turn
allowed for benchmarking against criteria set by national
guidelines. One respondent (GP1-INT) acknowledged that
the existing alerts embedded within the system could be
used, but that they were unwieldy because of their large
number so were not commonly used. Similarly, one CCG
Pharmacist (CCGP2) said there was a lack of confidence in
these alerts, because of a lack of knowledge about the con-
tent of the underlying algorithms used to generate theTable 4 Context-Mechanism-Outcome configurations concerning th
Context Mechanism
Clinical Commissioning Group engagement
with prescribing alerts
Alerts designed an
fowarded to pract
Identify specific pa
Monitoring prescribing by conducting searches
based upon local “initiatives”
Efficient use of tim
Highlight suboptim
prescribing
Reward good pracexisting alerts, so they were seldom used. The engagement
with prescribing alerts also allowed the activation of a
mechanism for identifying specific patients, which was
seen as more likely to lead to a timely review of patients.
“You [can] pin [the alert] to [specific patients]. So if
you say […] metformin shouldn’t be prescribed with an
eGFR less than 30 and these are the patients who you
need to consider in this category it’s such a more
meaningful event.” (GP1-INT)
The second context concerned the CCG setting up their
own searches based upon local initiatives. Within this con-
text one mechanism allowed for searches to be conducted
speedily across all practices within the CCG. This was a
change in working, where in the past “trawling round all
[…] practices” (CCGP2) had “[taken] us about three to four
weeks” (GP1-INT). Since the introduction of the interven-
tion, “we ran the same search and literally […] 90 min
without actually leaving your desk, you’ve got the results”
(GP1-INT). Using the system helped to identify prescribing
patterns and “to have the ability to look at the prescribing
by practice […] so we could compare […] the prescribing of
a drug one practice to another” (GP1-INT). Participants
saw this as leading to prescribing patterns being bench-
marked across the CCG. Additionally, the EMOS was seen
as an educational tool that could reduce knowledge gaps
and change prescribing behaviour by highlighting subopti-
mal prescribing within and across practices “because we
could identify those patients receiving whatever strength,
notify GP within the system and […] got 100% adherence to
this safety thing”(GP1-INT). This educational outcome was
further enhanced by rewarding good practice: “if there are
some practices that are demonstrating very good prescrib-
ing, then we’ve picked those out as well and highlighted
those” (CCGP2).
Work practices
The final group of CMOs concerned the effect of the
EMOS on work practices (Table 5). This involved a
number of different stakeholders in general practices:
GPs; practice managers; and practice-based pharmacists.e monitoring of prescribing
Outcome
d results
ices
Prescribing patterns and trends benchmarked
against national targets and guidelines
tients Pre-emptive or timely review of individual patients
e Prescribing patterns benchmarked across the Clinical
Commissioning Group
al Reduction of knowledge gaps to optimise use
of medicines
tice
Table 5 Context-Mechanism-Outcome configurations concerning work practices
Context Mechanism Outcome
Multiple administrative work
practices
Logging on, responding to alert, and
reviewing patients through the system
Patients reviewed to ensure appropriate monitoring, to optimise
medications, or to avoid hazardous combinations of drugs
Pre-existing division of labour
within General Practices
Task allocation
General Practice workload Task Prioritisation Pre-emptive or timely review of individual patient
Pharmacist workload Existing work practices developed and
adapted
Can result in a more focused medication review
Pharmacist undertaking
reviews in care homes
Accessing easily readable and informative
data
Necessary workarounds to overcome
technical issues
Necessary workarounds to find patient
details
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practices. Some practices relied on alerts being sent to
them by email rather than proactively seeking the alerts
by logging on to the EMOS. The process of responding
to alerts varied, but often involved transferring informa-
tion from email to paper in addition to logging on to the
system, causing a delay.
“The alert is printed off on a piece of paper which
[then] sits in my in tray with 500 other items of equal
urgency, and […] it might be that I have to work my
way down through that pile over a period of a few
months.” (GP4)
Reviewing the patient through the system was a more
successful mechanism that gave immediate feedback to
the CCG, avoided the delays, and provided clear and
speedily accessible information in a readable form where:
“you can plot the graphs [and] quickly eyeball 100 patients
in a couple of minutes.” (GP1-INT)
Within the context of pre-existing divisions of labour
within practices, EMOS was seen to require a specific task
allocation which would be “certainly led by a clinician
and most likely performed by a clinician” (GP4). There
was variation in the ways the EMOS was used by either
practice managers or GPs. One practice manager said that
once an alert was received they took responsibility for it:
“I pass it on to the GP and get them to respond to me,
and then I update Eclipse […] the doctor’s don’t access
it at all” (GPM2)
Whereas in another practice the responsibility for
accessing the system was the GP’s:
“The GP actions it, I don’t have any more
responsibility for it after that […] They go into Eclipse,
they do it, […] I had to remind one GP today, I justwanted to check they had actually reviewed this
patient” (GPM1)
If the system was used effectively then patients would
be reviewed but, as noted by the general practice man-
ager above, it was possible that the task allocation could
act as a blocking mechanism (that is, inhibiting the ef-
fect of the system) if GPs had to be reminded to review
patients.
Within the GP workload context, mechanisms associ-
ated with task prioritisation could lead to the timely re-
view of patients. To utilise the system effectively, GPs
had to juggle competing tasks and prioritise. If GPs were
“getting pertinent alerts that they feel are relevant” these
alerts were seen with “virtually no negativity.” (GP1-FG)
For pharmacists undertaking medication reviews in
care homes, the system saved time by giving more
speedy access to information, “there and then in front of
you” (CCGP1) allowing for a more focused review. The
system gave the pharmacist the opportunity to send rec-
ommendations to the GP based on information about
medications, test results, conditions and demographic
factors. This information was easily accessed through
the EMOS and findings easily interpreted.
“The benefit of Eclipse is you can log on and look at
the graph and you can see the basic trend of blood
pressure, of cholesterol, of weight et cetera, on a
beautiful graph which is so easy to read with the red/
amber/green bits, it’s so clear what’s going on.”
(CCGP1)
Effective use of the system required some adaptations
and improvisation on the part of the users. For example
participant CCGP1 whilst carrying out tasks in a care
home, had to adapt ways of obtaining passwords for the
system to deal with limited internet access. Pharmacists
“beforehand were trying to look up all the stuff on Eclipse
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adapted their activities in order to have “more informa-
tion to start off with (and) use Eclipse for less time in the
care home, but in a more directed manner” (CCGP1).
Limitations to the information available in the system,
necessitated workarounds in order to obtain further pa-
tient details; “because it doesn’t list actual allergies”
(CCGP1) and “we can’t look at letters” (CCGP1). This
meant finding out more information from the general
practices before the visit to the care home or returning
to general practices to obtain “any relevant letters from
consultants or anything like that” (CCGP1).
Discussion
Our study has identified variations in stakeholders’ expe-
riences of the IT intervention across primary care, which
potentially affects its successful implementation. The
capacity to audit prescribing across practices allowed for
the practices to be benchmarked. One particular benefit
of the EMOS is the ability to swiftly review specific pa-
tients and groups of patients to ensure they have appro-
priate monitoring, to optimise dosages or to avoid
hazardous combinations of medicines, which may result
in safer prescribing. The system was valued by the clini-
cians and pharmacists placed centrally at the CCG be-
cause it could be utilised to access prescribing
information and could lead to the timely review of pa-
tients at risk of adverse drug events. There was a sense
that the system was for the CCG and owned by them.
This created barriers to use elsewhere. Centrally the
CCG encouraged access to general practices but could
limit the engagement for others. There was therefore a
“top down” implementation that was dependent upon
soft governance from the CCG in the form of incentives
and permission for access. Elsewhere, the value of the
EMOS was dependent upon two factors: the flow of in-
formation and work practices.
Consistent with previous literature, participants in
our study had adapted work practices to use the EMOS
[13, 19]. Whilst prioritising tasks and enacting work-
arounds contributed to effective use of the system,
some work practices acted as blocking mechanisms; for
instance, underutilising the system by making paper
copies of alerts that were designed to be read and
responded to on screen. In a study of GP practices’
handling of secondary care information, [33] delays
were seen to be caused by similar sub-optimal work
practices.
It was perceived that the flow of information between
the CCG and individual practices facilitated engagement
with the system. Practices were more engaged when
alerts were limited, more relevant and the system was
trimmed down to local alerts based on local projects ra-
ther than using a whole catalogue of embedded alertswithin the system. Consistent with previous research this
tailoring of alerts allowed for time saving, avoided alert
fatigue [12] and so encouraged greater engagement.
Ojeleye and colleagues [34] have likewise found that the
tailoring of alerts maximised the likelihood of action be-
ing taken. Where practices logged in to the EMOS to re-
view patients they provided feedback to the CCG that
they were proactively engaging with the system. In our
study this engagement was said to have an educational
impact similar to previous findings [35].
Strengths and weaknesses
The particular strength of this study is the novel use of a
realist evaluation approach to examine an information
technology intervention in primary care. This allowed us
to explore in detail the ways the EMOS was used and
the potential effect this had on medication safety out-
comes. Recent guidelines advise that evaluation should
examine in detail how the intervention works and the
interactions of different stakeholders [36].
A potential limitation of our study was that it focused
upon one single CCG. Whilst there was inclusion of all
relevant stakeholders the number of participants in each
group was small given the size of the case study. The
CCG had been an early adopter of this EMOS but it was
used less widely than anticipated. This limited our un-
derstanding of how the system could be used by the
widest range of stakeholders and in different contexts
within primary care particularly since the use in commu-
nity pharmacy and among patients was limited. Due to
the nature of our study design, we were reliant upon re-
spondents’ subjective accounts and were unable to assess
the medication safety outcomes directly.
Implications for medicines management and further
research
Consistent with other literature around the implementa-
tion of IT systems [13, 17, 37, 38], our findings show
how disengagement from the system undermined its ef-
fectiveness. Sociotechnical approaches have understood
the implementation of IT in terms of an interaction be-
tween the technology and the human. Our findings
highlight implications for the implementation of other
IT systems in medicines management, and more broadly
in healthcare, and that they may be understood from a
sociotechnical view.
Specifically, we found that greater ownership of the
system across the workforce, and more embeddedness
within existing work practices [37], could lead to better
utilisation across primary care, with potential benefits
for medication safety. The use of the system was under-
mined by a perception amongst several stakeholders that
the EMOS was owned by the CCG. Partly this percep-
tion was the design of the system as a tool to be used
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for the system to be used locally, was undermined by the
ownership of it by the CCG and by the understanding
that it was a population level audit tool. Utilisation was
further undermined by time pressures in general prac-
tice, a lack of access to and a lack of knowledge and
awareness of the potential benefits of utilising the
EMOS. Participants in our study speculated that general
practices more engaged in the use of the system might
have dedicated prescribing leads who are more likely to
run their own audits and as such were more proactive in
managing medication risks. The lack of involvement
from a broader range of stakeholders, including commu-
nity pharmacists and patients, prevented the exploitation
of potential benefits of the EMOS in enhancing shared
care, self-management and medication reviews; all of
which could have an impact upon medication safety.
Our realist evaluation was a case study was of a single
CCG. We suggest that the CMO configurations we con-
ceptualized here would be valuably applied to further
evaluation of this system in use in other CCG areas, in a
process of cumulation and further theory testing [22].
This would build upon how the system could be further
implemented. Furthermore our study CCG was a pre-
dominantly rural area with a relatively small number of
general practices and all practices used the same clinical
system. Further research on the use of this EMOS in
other CCGs, where different clinical systems are used,
might lead to different contexts being identified; for ex-
ample, busier urban practices might have high staff turn-
over, which creates greater variations in prescribing
behaviour and user interaction [12]. A realist evaluation
of this EMOS might also be run in a longitudinal man-
ner, alongside the implementation of the intervention.
This would help to track changes to work practices as
the intervention was embedded into existing work be-
haviour [39, 40].
There are wider implications for the evaluation and im-
plementation of other IT systems in primary care. In our
realist study, contexts were not only time and space but
also pre-existing work practices, workload and divisions of
labour. IT systems in healthcare are often interrelated, and
their interactions with users vary and evolve over time
[41]. This creates complexity in the way that healthcare
organisations operate [15, 32]. Future evaluations of
healthcare IT systems could look to realist evaluation as a
way of unpicking this complexity in order to optimise
their use.
Conclusions
The implementation and adoption of an electronic medi-
cines optimisation system may improve medication safety
in primary care settings by identifying those patients at
risk of an adverse drug event. However the use of such asystem was found to be dependent upon adapting work
practices and undermined by perceptions of ownership,
lack of access, lack of knowledge and awareness, and ex-
pectations concerning variable task allocation. As a result
some stakeholders had limited or no engagement with the
system.
To fully realise the potential benefits for medication
safety of the EMOS, there needs to be better utilisation
across primary care and with a wider range of stake-
holders. Future roll out of this system might consider
how perceptions of ownership might impact upon util-
isation. Engaging with all potential stakeholders and
users prior to implementation might not only allay a
sense that the system is owned centrally but increase
knowledge and awareness of the potential benefits of the
system. We found that realistic evaluation was a valuable
approach to unpick the complexity of an IT intervention
in primary care and would recommend that this ap-
proach is adopted for similar evaluations.
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